LINEAGE CELL THERAPEUTICS IN (LCTX) Institutional Ownership Changes & 13F Activity
LINEAGE CELL THERAPEUTICS IN (LCTX). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Millennium Management Llc, Armistice Capital, Llc, Marshall Wace, Llp, Susquehanna International Group, Llp, and Citadel Advisors Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Western Wealth Management, Llc | Buy | +300 | — | 300 | $474.00 | Q1 2026 | May 19, 2026 |
| Bank Of America Corp | Buy | +221,506 | +112.0% | 419,355 | $662.58K | Q1 2026 | May 18, 2026 |
| Sunbelt Securities, Inc. | Buy | +2,000 | — | 2,000 | $3.16K | Q1 2026 | May 18, 2026 |
| Millennium Management Llc | Buy | +3,450,955 | +163.5% | 5,561,374 | $8.79M | Q1 2026 | May 15, 2026 |
| Armistice Capital, Llc | Buy | +3,182,799 | — | 3,182,799 | $5.03M | Q1 2026 | May 15, 2026 |
| Marshall Wace, Llp | Buy | +1,702,972 | +125.0% | 3,065,033 | $4.84M | Q1 2026 | May 15, 2026 |
| Susquehanna International Group, Llp | Buy | +598,270 | +84.7% | 1,304,685 | $2.06M | Q1 2026 | May 15, 2026 |
| Citadel Advisors Llc | Sell | -376,104 | -74.2% | 130,948 | $206.90K | Q1 2026 | May 15, 2026 |
| Goldman Sachs Group Inc | Sell | -269,319 | -18.7% | 1,169,427 | $1.85M | Q1 2026 | May 15, 2026 |
| Brevan Howard Capital Management Lp | Buy | +186,794 | — | 186,794 | $295.13K | Q1 2026 | May 15, 2026 |
| Two Sigma Investments, Lp | Sell | -177,000 | -66.6% | 88,585 | $139.96K | Q1 2026 | May 15, 2026 |
| Omers Administration Corp | Sell | -174,200 | -61.5% | 109,000 | $172.22K | Q1 2026 | May 15, 2026 |
| Point72 Asset Management, L.P. | Buy | +144,955 | +90.9% | 304,363 | $480.89K | Q1 2026 | May 15, 2026 |
| Morgan Stanley | Sell | -130,172 | -6.5% | 1,868,491 | $2.95M | Q1 2026 | May 15, 2026 |
| Jain Global Llc | Buy | +83,200 | +214.2% | 122,051 | $192.84K | Q1 2026 | May 15, 2026 |
| Squarepoint Ops Llc | Buy | +78,081 | +119.9% | 143,190 | $226.24K | Q1 2026 | May 15, 2026 |
| State Street Corp | Buy | +73,900 | +7.3% | 1,090,111 | $1.72M | Q1 2026 | May 15, 2026 |
| Geode Capital Management, Llc | Buy | +61,921 | +2.5% | 2,523,114 | $3.99M | Q1 2026 | May 15, 2026 |
| Diametric Capital, Lp | Buy | +59,029 | — | 59,029 | $93.27K | Q1 2026 | May 15, 2026 |
| Qube Research & Technologies Ltd | Buy | +48,213 | +22.8% | 259,561 | $410.11K | Q1 2026 | May 15, 2026 |
| Barclays Plc | Buy | +44,799 | +12.9% | 393,309 | $621.43K | Q1 2026 | May 15, 2026 |
| Summittx Capital, L.P. | Buy | +39,514 | +185.3% | 60,833 | $96.12K | Q1 2026 | May 15, 2026 |
| Schonfeld Strategic Advisors Llc | Buy | +34,699 | +260.5% | 48,017 | $75.87K | Q1 2026 | May 15, 2026 |
| Lmr Partners Llp | Buy | +21,160 | — | 21,160 | $33.43K | Q1 2026 | May 15, 2026 |
| Quantessence Capital Llc | Buy | +16,281 | — | 16,281 | $25.72K | Q1 2026 | May 15, 2026 |
| Prelude Capital Management, Llc | Buy | +14,942 | — | 14,942 | $23.61K | Q1 2026 | May 15, 2026 |
| Voleon Capital Management Lp | Buy | +14,771 | +20.8% | 85,739 | $135.47K | Q1 2026 | May 15, 2026 |
| Xtx Topco Ltd | Sell | -9,913 | -23.4% | 32,368 | $51.14K | Q1 2026 | May 15, 2026 |
| Tower Research Capital Llc (Trc) | Buy | +3,716 | +19.1% | 23,187 | $36.63K | Q1 2026 | May 15, 2026 |
| Two Sigma Securities, Llc | Sell | -3,208 | -13.6% | 20,390 | $32.22K | Q1 2026 | May 15, 2026 |
Frequently asked questions about LCTX activity
Which institutional owners are buying LCTX?
Institutional owners buying LCTX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in LCTX activity?
"Buy" means an investor increased their reported position in LCTX compared to the prior reporting period. This reflects growing exposure to LINEAGE CELL THERAPEUTICS IN (LCTX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in LCTX increasing?
Institutional interest in LCTX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related LCTX Institutional Insights
- LCTX Overview
- LCTX 13F Institutional Holders
- LCTX Superinvestors
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- LCTX Insider Trading & SEC Form 4 Activity
- LCTX Articles
- Top Institutional Investor Stock Rankings